Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Important TIPS for KOL Mapping
Summary
In this episode, Keely Dahl shares her expertise on KOL mapping, offering valuable insights into identifying and ranking key opinion leaders. She outlines the importance of cross-functional coordination in engaging with KOLs and provides strategies for acquiring meetings and optimizing contact lists. Keely discusses effective outreach methods, including email and phone communication, and emphasizes the significance of networking at conferences. The episode concludes with best practices for email communication and essential advice for MSLs aiming to enhance their KOL mapping skills.
Keely Dahl, Sr Medical Science Liaison at Aurinia Pharmaceuticals shares important tips for KOL mapping based on her real life experience
Keely shares…
π What is KOL Mapping and how to build your list
π Best ways to coordinate with cross functional partners
π Unique ways to engage with KOLs and gain better access
π How to maintain and prioritize your list
π Advice for closing out the year on a strong note
KOL mapping, key opinion leaders, cross-functional coordination, outreach methods, Medical Science Liaison
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary